Probi AB (publ) has completed the first commercial production batches of a dairy-free Streptococcus salivarius BLIS K12 at its U.S. manufacturing site. The new BLIS strains will shortly be offered to customers around the world. Probi entered a strategic partnership with New Zealand based Blis Technologies Ltd. as part of a long-term strategic collaboration in July, 2021.

As part of this partnership, Probi and Blis signed a licensing and distribution agreement. Probi is now manufacturing BLIS® strains at its recently upgraded fermentation facility in Redmond, WA and will shortly be offering these new strains to Probi's customers around the world. In addition, the two companies are continuing to collaborate on additional research and development.